Our VisionTaliaz Diagnostics will have a meaningful role in the field of genetic-based personalized medicine, through the development of genetic-based diagnostic tools that increase efficiency, efficacy and accuracy of medications.

Our Antidepressant Predictive ToolTaliaz Diagnostics’ first product is a tested and validated tool, developed to guide clinicians in prescribing the most suitable antidepressant medication for each patient.

Our Unique SolutionOur tool guides clinicians to match drugs more accurately to individual patients. By combining our expertise in genetics & strong clinical knowledge together with our machine learning algorithm expertise we have generated a unique solution which increases treatment success rates to 70%.

Our algorithm analyzes the patient’s DNA sequence and clinical background to determine the best treatment. We analyze 180 distinct genetic alterations, compared to the conventional 15 alterations explored by existing methods. Using this information, we can predict the medication the patient will best respond to and the severity of its side effects. We then recommend the most suitable antidepressant medication and dosage that presents the least side effects.

Our tool is the only one to be tested and validated using the largest existing dataset of patients’ response to a range of antidepressants, obtained from the NIH.

The NeedIn the US, five million patients start treatment for depression each year. There are dozens of antidepressant medications on the market today, and patients respond differently to each. While only 39% of patients recover after the first treatment, typical treatment is conducted for months by trial and error process.

There is a clear need for a decision support tool which would allow the physician to make an educated decision when matching a treatment to each patient.

Mobile: +972-(0)53-8223951, TeleFax: +972-(0)77-3352506, Email: dekel@taliazdx.com2 Prof. Yehezkel Kaufmann Street, Tel-Aviv, Textile Center, 17th Floor, post-code 6801294www.taliazdiagnostics.com

The MarketThe application of our platform in the field of psychiatric disorders alone has tremendous market potential. 1 in 10 adults take antidepressant medications in the US. Major Depressive Disorder remains the leading cause of disability among people aged 15-44. Depression is estimated to cost the US economy over $80 billion each year.

In this environment Taliaz Diagnostics expects to reach sales of a million test kits annually in the US. This forecast does not include the European, Indian and Israeli markets we are currently exploring.

The TeamWith years of experience in the areas of bioinformatics and neuroscience, our team generates high-quality research and develops innovative and practical products. Our unique combination of deep machine learning skills, neuroscience and genome expertise sets us apart and provides us with the necessary capacities to have an impact in our target market. These strengths are supported by the right mix of strategy, operations and business skill sets to drive Taliaz Diagnostics towards reaching its short and long-term business goals.

1 million test kits annually

Dr. Dekel Taliaz, PhDCTO & Co-founder

Experimental neuroscientist. Expert in using molecular methods to manipulate gene expression to determining genetic factors which underlie psychiatric disorders.

Oren TaliazCEO & Co-founder

Experienced CEO with critical skills in driving mission and strategy, budget and investment management. Founder of a successful capital markets firm specializing in foreign currency.

Dr. Zohar Barnet Itzhaki, PhDVP R&D

Bioinformatician with over 10 years of experience in academia and private sector. Expert in the statistical analysis of genetic variations and in the development of machine learning algorithms.

Prof. Bernard Lerer, MDBiological Psychiatry Specialist

World renowned psychiatrist and researcher. Head and founder of the Biological Psychiatry laboratory at Hadassah-Hebrew University Medical Center. Expert in understanding the role of genetic factors in response to psychiatric drugs.

Brian SteinbergerVP Business Development

Seasoned business executive with extensive expertise in operations management and and business development, overseeing cross-regional expansions, strategy design & implementation for global provider of algorithmic platforms.

Dr. Ran Barzilay, MD, PhDVP Clinical Studies

Psychiatric neuroscientist. Resident psychiatrist with experience in basic and translational neuroscience with a focus on stress related disorders.